Evidence map›Paper›PMID 37043280›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2023

Prediagnostic Glycoprotein Acetyl Levels and Incident and Recurrent Flare Risk Accounting for Serum Urate Levels: A Population-Based, Prospective Study and Mendelian Randomization Analysis.

Amit D Joshi, Natalie McCormick, Chio Yokose, Bing Yu, Adrienne Tin, Robert Terkeltaub, Tony R Merriman, A Heather Eliassen, Gary C Curhan, Laura M Raffield and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 3 countries.

Amit D Joshi *Clinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital, Boston.
Natalie McCormick *Clinical Epidemiology Program, Division of Rheumatology, Allergy, and Immunology, and The Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston, and Department of Medicine, Harvard Medical School, Boston, Massachusetts, and Arthritis Research Canada, Vancouver, British Columbia, Canada.ORCID 0000-0002-4147-8348
Chio YokoseClinical Epidemiology Program, Division of Rheumatology, Allergy, and Immunology, and The Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston, and Department of Medicine, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-7557-3303
Bing YuDepartment of Epidemiology, Human Genetics and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston.
Adrienne TinDepartment of Medicine, University of Mississippi Medical Center, Jackson.ORCID 0000-0002-4207-5866
Robert TerkeltaubSan Diego VA Healthcare Service and University of California San Diego, La Jolla, California.
Tony R MerrimanDivision of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, and Department of Biochemistry, University of Otago, Dunedin, New Zealand.ORCID 0000-0003-0844-8726
A Heather EliassenDepartments of Nutrition and Epidemiology, Harvard TH Chan School of Public Health, Boston, Massachusetts, and Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Gary C CurhanChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Laura M RaffieldDepartment of Genetics, University of North Carolina at Chapel Hill.
Hyon K ChoiClinical Epidemiology Program, Division of Rheumatology, Allergy, and Immunology, and The Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston, and Department of Medicine, Harvard Medical School, Boston, Massachusetts, and Arthritis Research Canada, Vancouver, British Columbia, Canada.ORCID 0000-0002-2862-0442
Harvard University · USBrigham and Women's Hospital · USJackson Memorial Hospital · USMcCormick Theological Seminary · USThe University of Texas Health Science Center at Houston · USUniversity of Alabama at Birmingham · USUniversity of California San Diego · USUniversity of North Carolina at Chapel Hill · US

Funding

The Effects of Urate Lowering Therapy on Inflammation, Endothelial function, andP50AR060772 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SAAG, KENNETH G · 2012 to 2021
$12.8M
NOVEL METABOLITE AND MICROBIOTA PATHWAYS FOR HYPERURICEMIA AND GOUTR01AR065944 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI CHOI, HYON K · 2013 to 2025
$4.2M
Metabolic syndrome, chronic inflammation, and gout: a multi-omics approachR00AR080243 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI Natalie McCormick · 2025 to 2026
$461k
Metabolic syndrome, chronic inflammation, and gout: a multi-omics approachK99AR080243 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI MCCORMICK, NATALIE · 2022 to 2023
$188k
Intersections of matrix biology with inflammation in a new model of goutI01BX005927 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI TERKELTAUB, ROBERT A. · 2023 to 2023
–
BLRD VA I01 BX005927NIAMS NIH HHS K99 AR080243NIAMS NIH HHS P50 AR060772NIAMS NIH HHS R00 AR080243NIAMS NIH HHS R01 AR065944
6 · The paper itself

Abstract

objectiveTo prospectively investigate population-based metabolomics for incident gout and reproduce the findings for recurrent flares, accounting for serum urate.

methodsWe conducted a prediagnostic metabolome-wide analysis among 105,615 UK Biobank participants with nuclear magnetic resonance metabolomic profiling data (168 total metabolites) from baseline blood samples collected 2006-2010 in those without history of gout. We calculated hazard ratios (HRs) for incident gout, adjusted for gout risk factors, excluding and including serum urate levels, overall and according to fasting duration before sample collection. Potential causal effects were tested with 2-sample Mendelian randomization. Poisson regression was used to calculate rate ratios (RRs) for the association with recurrent flares among incident gout cases.

resultsCorrecting for multiple testing, 88 metabolites were associated with risk of incident gout (N = 1,303 cases) before serum urate adjustment, including glutamine and glycine (inversely), and lipids, branched-chain amino acids, and most prominently, glycoprotein acetyls (GlycA; P = 9.17 × 10

conclusionThis prospective, population-based study implicates GlycA, a stable long-term biomarker reflecting neutrophil overactivity, in incident and recurrent gout flares (central manifestation from neutrophilic synovitis) beyond serum urate.

Indexed as

GoutUric AcidGlycoproteinsHumansMendelian Randomization AnalysisProspective StudiesRisk FactorsGlycoproteinsUric Acid

Identifiers

PMID37043280
PMCPMC10524152
OpenAlexW4365135323

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.